163 related articles for article (PubMed ID: 36975820)
1. Long-term Survival in Breast Cancer Patients Is Associated with Contralateral Parenchymal Enhancement at MRI: Outcomes of the SELECT Study.
Ragusi MAA; van der Velden BHM; Meeuwis C; Tetteroo E; Coerkamp EG; van Nijnatten TJA; Jansen FH; Wolters-van der Ben EJM; Jongen L; van Raamt F; Dorrius MD; Verloop J; Viergever MA; Pijnappel RM; Elias SG; Gilhuijs KGA
Radiology; 2023 May; 307(4):e221922. PubMed ID: 36975820
[TBL] [Abstract][Full Text] [Related]
2. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
[TBL] [Abstract][Full Text] [Related]
3. Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients.
van der Velden BHM; Sutton EJ; Carbonaro LA; Pijnappel RM; Morris EA; Gilhuijs KGA
Eur Radiol; 2018 Nov; 28(11):4705-4716. PubMed ID: 29736850
[TBL] [Abstract][Full Text] [Related]
4. Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER
van der Velden BHM; Elias SG; Bismeijer T; Loo CE; Viergever MA; Wessels LFA; Gilhuijs KGA
Clin Cancer Res; 2017 Nov; 23(21):6505-6515. PubMed ID: 28790119
[No Abstract] [Full Text] [Related]
5. Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index.
Ragusi MAA; Loo CE; van der Velden BHM; Wesseling J; Linn SC; Beets-Tan RG; Elias SG; Gilhuijs KGA
Eur Radiol; 2020 Dec; 30(12):6740-6748. PubMed ID: 32691100
[TBL] [Abstract][Full Text] [Related]
6. Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?
van der Velden BHM; Bismeijer T; Canisius S; Loo CE; Lips EH; Wesseling J; Viergever MA; Wessels LFA; Gilhuijs KGA
Eur J Radiol; 2019 Dec; 121():108705. PubMed ID: 31655316
[TBL] [Abstract][Full Text] [Related]
7. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
8. Effects of Preoperative Breast MRI on Breast Cancer Survival Outcomes in Women Aged 35 Years and Younger.
Park AR; Chae EY; Kim HJ; Cha JH; Shin HJ; Choi WJ; Kim HH
Radiology; 2023 May; 307(4):e221797. PubMed ID: 36975814
[TBL] [Abstract][Full Text] [Related]
9. Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer.
Nguyen D; Yu J; Reinhold WC; Yang SX
JAMA Netw Open; 2020 Jul; 3(7):e207213. PubMed ID: 32644137
[TBL] [Abstract][Full Text] [Related]
10. Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients.
Ragusi MAA; Bismeijer T; van der Velden BHM; Loo CE; Canisius S; Wesseling J; Wessels LFA; Elias SG; Gilhuijs KGA
Breast; 2021 Dec; 60():230-237. PubMed ID: 34763270
[TBL] [Abstract][Full Text] [Related]
11. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
Sinha AK; Patel JR; Shen Y; Ueno NT; Giordano SH; Tripathy D; Lopez DS; Barcenas CH
PLoS One; 2017; 12(1):e0170081. PubMed ID: 28085940
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy.
Ito M; Amari M; Sato A; Hikichi M; Sakamoto A; Yamazaki A; Saji S
Breast; 2024 Feb; 73():103604. PubMed ID: 38000091
[TBL] [Abstract][Full Text] [Related]
13. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Gonzalez-Angulo AM; Litton JK; Broglio KR; Meric-Bernstam F; Rakkhit R; Cardoso F; Peintinger F; Hanrahan EO; Sahin A; Guray M; Larsimont D; Feoli F; Stranzl H; Buchholz TA; Valero V; Theriault R; Piccart-Gebhart M; Ravdin PM; Berry DA; Hortobagyi GN
J Clin Oncol; 2009 Dec; 27(34):5700-6. PubMed ID: 19884543
[TBL] [Abstract][Full Text] [Related]
14. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
15. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
16. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
Reddy SM; Barcenas CH; Sinha AK; Hsu L; Moulder SL; Tripathy D; Hortobagyi GN; Valero V
Br J Cancer; 2018 Jan; 118(1):17-23. PubMed ID: 29235566
[TBL] [Abstract][Full Text] [Related]
19. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
20. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
